目标:全球,已经报告了超过7.72亿例COVID-19病例。在病例编号中具有相应尖峰的感兴趣的新变体继续被鉴定。脆弱的病人,包括老年人或患有严重合并症的患者,继续处于危险之中。关于抗SARS-CoV-2-抗体和COVID-19的大量证据已经积累,但抗体测量的有用性仍不清楚。本系统综述旨在评估抗SARS-CoV-2抗体的预后价值及其对指导加强疫苗接种的有用性。
方法:包括2020年1月至2023年10月发表的英文研究。依赖于多参数模型或包含少于100名参与者的研究被排除在外。PubMed和通过WHOCOVID-19研究数据库,检索Embase和Medline数据库。研究选择和质量评估由两名研究人员独立进行。
结果:在筛选1,160项研究后,包括超过3000万个体的33项研究。抗SARS-CoV-2抗体与降低SARS-CoV-2感染的风险和更好的结果密切相关。包括死亡率。感染风险和COVID-19严重程度随着抗体水平的增加而降低。
结论:抗SARS-CoV-2-抗体有助于早期识别高危患者并及时调整治疗方案。可以应用保护阈值来建议加强疫苗接种,但需要在单独的队列中进行验证。
OBJECTIVE: Globally, over 772 million cases of COVID-19 have been reported. New variants of interest with corresponding spikes in case numbers continue to be identified. Vulnerable patients, including older adults or patients with severe comorbidities, continue to be at risk. A large body of evidence has been accumulated regarding anti-SARS-CoV-2-antibodies and COVID-19 but the usefulness of antibody measurements remains unclear. This systematic
review aims to assess the prognostic value of anti-SARS-CoV-2-antibodies and their usefulness for guiding booster vaccinations.
METHODS: Studies in English and published between January 2020 and October 2023 were included. Studies that relied on multiparameter-models or comprised fewer than 100 participants were excluded. PubMed and via the WHO COVID-19 research database, Embase and Medline databases were searched. Study selection and quality assessment was conducted independently by two researchers.
RESULTS: After screening 1,160 studies, 33 studies comprising >30 million individuals were included. Anti-SARS-CoV-2-antibodies were strongly associated with reduced risk of SARS-CoV-2-infection and better outcomes, including mortality. Risk of infection and COVID-19 severity decreased with increasing antibody levels.
CONCLUSIONS: Anti-SARS-CoV-2-antibodies are useful for early identification of high-risk patients and timely adjustment of therapy. Protective thresholds may be applied to advise booster vaccinations but verification in separate cohorts is required.